These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33285182)

  • 1. Rapid Developability Assessments to Formulate Recombinant Protein Antigens as Stable, Low-Cost, Multi-Dose Vaccine Candidates: Case-Study With Non-Replicating Rotavirus (NRRV) Vaccine Antigens.
    Sawant N; Kaur K; Holland DA; Hickey JM; Agarwal S; Brady JR; Dalvie NC; Tracey MK; Velez-Suberbie ML; Morris SA; Jacob SI; Bracewell DG; Mukhopadhyay TK; Love KR; Love JC; Joshi SB; Volkin DB
    J Pharm Sci; 2021 Mar; 110(3):1042-1053. PubMed ID: 33285182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Aluminum Adjuvant and Preservatives on Structural Integrity and Physicochemical Stability Profiles of Three Recombinant Subunit Rotavirus Vaccine Antigens.
    Agarwal S; Hickey JM; McAdams D; White JA; Sitrin R; Khandke L; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):476-487. PubMed ID: 31589875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of Thimerosal-Induced Structural Destabilization of a Recombinant Rotavirus P[4] Protein Antigen Formulated as a Multi-Dose Vaccine.
    Kaur K; Xiong J; Sawant N; Agarwal S; Hickey JM; Holland DA; Mukhopadhyay TK; Brady JR; Dalvie NC; Tracey MK; Love KR; Love JC; Weis DD; Joshi SB; Volkin DB
    J Pharm Sci; 2021 Mar; 110(3):1054-1066. PubMed ID: 33278412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the Compatibility of New Recombinant Protein Antigens (Trivalent NRRV) with a Mock Pentavalent Combination Vaccine Containing Whole-Cell Pertussis: Analytical and Formulation Challenges.
    Kumar P; Holland DA; Secrist K; Taskar P; Dotson B; Saleh-Birdjandi S; Adewunmi Y; Doering J; Mantis NJ; Volkin DB; Joshi SB
    Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of Aluminum-adjuvanted Recombinant P[4] Protein Antigen With Preservatives: Storage Stability and Backbone Flexibility Studies.
    Sawant N; Joshi SB; Weis DD; Volkin DB
    J Pharm Sci; 2022 Apr; 111(4):970-981. PubMed ID: 34758340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erratum to "Rapid developability assessments to formulate recombinant protein antigens as stable, low-cost, multi-dose vaccine candidates: Case-study with non-replicating rotavirus (NRRV) vaccine antigens" [J Pharm Sci 110 (2021) 1042-1053].
    J Pharm Sci; 2021 Apr; 110(4):1867. PubMed ID: 33662392
    [No Abstract]   [Full Text] [Related]  

  • 7. Formulation and preclinical studies with a trivalent rotavirus P2-VP8 subunit vaccine.
    Lakatos K; McAdams D; White JA; Chen D
    Hum Vaccin Immunother; 2020 Aug; 16(8):1957-1968. PubMed ID: 31995444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of trivalent non-replicating rotavirus vaccine antigens in the presence of aluminum adjuvant.
    McAdams D; Lakatos K; Estrada M; Chen D; Plikaytis B; Sitrin R; White JA
    J Immunol Methods; 2021 Jul; 494():113056. PubMed ID: 33857473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine.
    Agarwal S; Sahni N; Hickey JM; Robertson GA; Sitrin R; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):394-406. PubMed ID: 31400346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine candidate for rotavirus.
    Dalvie NC; Brady JR; Crowell LE; Tracey MK; Biedermann AM; Kaur K; Hickey JM; Kristensen DL; Bonnyman AD; Rodriguez-Aponte SA; Whittaker CA; Bok M; Vega C; Mukhopadhyay TK; Joshi SB; Volkin DB; Parreño V; Love KR; Love JC
    Microb Cell Fact; 2021 May; 20(1):94. PubMed ID: 33933073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical and Preformulation Characterization Studies of Human Papillomavirus Virus-Like Particles to Enable Quadrivalent Multi-Dose Vaccine Formulation Development.
    Jerajani K; Wan Y; Hickey JM; Kumru OS; Sharma N; Pullagurla SR; Ogun O; Mapari S; Whitaker N; Brendle S; Christensen ND; Batwal S; Mahedvi M; Rao H; Dogar V; Chandrasekharan R; Shaligram U; Joshi SB; Volkin DB
    J Pharm Sci; 2022 Nov; 111(11):2983-2997. PubMed ID: 35914546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystallization of a nonreplicating rotavirus vaccine candidate.
    Hong MS; Kaur K; Sawant N; Joshi SB; Volkin DB; Braatz RD
    Biotechnol Bioeng; 2021 Apr; 118(4):1750-1756. PubMed ID: 33527346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal purification method enables developability assessment of recombinant proteins.
    Rodriguez-Aponte SA; Naranjo CA; Johnston RS; Dalvie NC; Crowell LE; Bajoria S; Kumru OS; Joshi SB; Volkin DB; Love JC
    Biotechnol Bioeng; 2024 Aug; 121(8):2423-2434. PubMed ID: 36929469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inclusion of a universal tetanus toxoid CD4(+) T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus ΔVP8* subunit parenteral vaccines.
    Wen X; Wen K; Cao D; Li G; Jones RW; Li J; Szu S; Hoshino Y; Yuan L
    Vaccine; 2014 Jul; 32(35):4420-4427. PubMed ID: 24962749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries.
    Kumar P; Shukla RS; Patel A; Pullagurla SR; Bird C; Ogun O; Kumru OS; Hamidi A; Hoeksema F; Yallop C; Bines JE; Joshi SB; Volkin DB
    Hum Vaccin Immunother; 2021 Jul; 17(7):2298-2310. PubMed ID: 33861183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the long-term 2-8 °C stability profiles of a live, rotavirus vaccine candidate (RV3-BB) in various liquid formulations via extrapolations of real-time and accelerated stability data.
    Pullagurla SR; Kumar P; Ogun O; Kumru OS; Hamidi A; Hoeksema F; Yallop C; Bines JE; Volkin DB; Joshi SB
    Biologicals; 2022 Jan; 75():21-28. PubMed ID: 34924260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Subunit Rotavirus Trivalent Vaccine Candidate: Physicochemical Comparisons and Stability Evaluations of Three Protein Antigens.
    Agarwal S; Hickey JM; Sahni N; Toth RT; Robertson GA; Sitrin R; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):380-393. PubMed ID: 31400347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency.
    McAdams D; Estrada M; Holland D; Singh J; Sawant N; Hickey JM; Kumar P; Plikaytis B; Joshi SB; Volkin DB; Sitrin R; Cryz S; White JA
    Vaccine; 2022 Aug; 40(34):5069-5078. PubMed ID: 35871866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational design of heat stable lyophilized rotavirus vaccine formulations.
    Madan M; Sikriwal D; Sharma G; Shukla N; Mandyal AK; Kale S; Gill D
    Hum Vaccin Immunother; 2018; 14(9):2132-2141. PubMed ID: 29953317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of live attenuated rotavirus vaccine with selected preservatives and primary containers.
    Lal M; Jarrahian C; Zhu C; Hosken NA; McClurkan CL; Koelle DM; Saxon E; Roehrig A; Zehrung D; Chen D
    Vaccine; 2016 May; 34(22):2483-9. PubMed ID: 27085171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.